logo
A Clever One-Pot Salmon Dinner to Make Again and Again

A Clever One-Pot Salmon Dinner to Make Again and Again

New York Times28-05-2025
Recipe development may be an art, but it takes a whole lot of science to get there — especially if you're looking for convenience, too. One-pan recipes are engineering conundrums: How do you use a single vessel to get a mix of ingredients with unlike cooking times on the table simultaneously and delectably? The math, the chemistry and the thermodynamics all have to come together. For the cook, a one-pan recipe should be adaptable, instinctive and consistent. To create one takes brain work, creativity and a dollop of moxie.
Making full use of her background in food science, Yasmin Fahr crunches the numbers and nails the taste, as you can see for yourself in her ingenious one-pot miso-turmeric salmon with coconut rice. She builds the dish from the bottom of the pot up, starting by cooking the coconut rice, and next layering on spinach leaves, which act as a steamer basket to gently cook the fish. Finally, just before serving, a squeeze of lime brightens the whole thing. Once you've mastered the recipe's structure you can retool it however you want, swapping in chard, kale or lettuce for the spinach and other fish or tofu for the salmon. It's a marvel of engineering, one you can enjoy for dinner this very night.
Featured Recipe
View Recipe →
Vegetable yakisoba: More one-pot brilliance can be found in Kay Chun's vegetable-packed Japanese noodle stir-fry, which has a glossy Worcestershire-ketchup-oyster sauce that's tangy-sweet and deeply complex.
Easy chicken tacos: Boldly seasoned with hot sauce, onion powder and lime, boneless, skinless chicken thighs cook quickly and succulently in this 30-minute recipe by Kristina Felix. Piled into warm tortillas along with minced onion, cilantro and guacamole, this chicken makes for a weeknight recipe with panache for miles.
Want all of The Times? Subscribe.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)

Yahoo

time23 minutes ago

  • Yahoo

RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)

Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio

Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT
Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT

Yahoo

time23 minutes ago

  • Yahoo

Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT

AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) with a price target of $216.00. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) reported that net revenues in Q1 reached $13.343 billion, reflecting an 8.4% growth on a reported basis or 9.8% on an operational basis. Global net revenues for the quarter for the Immunology portfolio rose to $6.264 billion, reflecting a growth of 16.6% on a reported basis or 18.1% on an operational basis. AbbVie Inc. (NYSE:ABBV) also experienced growth in global net revenues in the Neuroscience portfolio to $2.282 billion, reflecting a 16.1% increase on a reported basis or 17% on an operational basis. AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target
Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target

Yahoo

time23 minutes ago

  • Yahoo

Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target

Johnson & Johnson (NYSE:JNJ) ranks among the . On July 16, Stifel maintained its Hold rating on Johnson & Johnson (NYSE:JNJ), but increased its price target for the healthcare giant from $155 to $165. The price target increase comes after JNJ revised its outlook, which now predicts adjusted operational revenue growth of roughly 3.5% instead of the 2.5% midpoint estimate that was previously projected. Pixabay/Public Domain Johnson & Johnson (NYSE:JNJ) also raised its outlook for full-year earnings per share from $10.50 to $10.70 to a range of $10.80 to $10.90. The company cited stronger top-line performance, currency effects, and a lower anticipated impact from tariffs for this improvement. From its initial estimate of $400 million, the healthcare company now projects a $200 million tariff impact in 2025. Johnson & Johnson (NYSE:JNJ) is a notable name in the healthcare industry, which includes sub-sectors like pharmaceuticals, medical equipment, and consumer health products. The company is known for creating medications to treat a variety of conditions and diseases, including cancer, diabetes, and HIV/AIDS. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store